Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNYSE:LLY Eli Lilly and Company (LLY) Stock Price, News & Analysis $1,418.32 +6.37 (+0.45%) As of 09:43 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eli Lilly and Company Stock (NYSE:LLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eli Lilly and Company alerts:Sign Up Key Stats Today's Range$1,416.00▼$1,416.0050-Day Range$1,115.53▼$1,418.1452-Week Range$850.51▼$1,453.00Volume22,274 shsAverage Volume2.96 million shsMarket Capitalization$1.33 trillionP/E Ratio45.98Dividend Yield0.49%Price Target$1,416.64Consensus RatingModerate Buy Company Overview Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas. Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world. David A. Ricks has served as Lilly’s chair and chief executive officer since 2017.AI Generated. May Contain Errors. Read More Eli Lilly and Company Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreLLY MarketRank™: 4.275501787185 of 5 starsEli Lilly and Company scored higher than 86% of companies evaluated by MarketBeat, and ranked 53rd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingEli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 24 buy ratings, 3 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Eli Lilly and Company is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEli Lilly and Company has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eli Lilly and Company's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth40.17% Earnings GrowthEarnings for Eli Lilly and Company are expected to grow by 40.17% in the coming year, from $35.70 to $50.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eli Lilly and Company is 45.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Eli Lilly and Company is 45.87, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.41.Price to Earnings Growth RatioEli Lilly and Company has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEli Lilly and Company has a P/B Ratio of 33.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.74% of the float of Eli Lilly and Company has been sold short.Short Interest Ratio / Days to CoverEli Lilly and Company has a short interest ratio ("days to cover") of 3.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eli Lilly and Company has recently decreased by 1.06%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldEli Lilly and Company has a dividend yield of 0.49%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthEli Lilly and Company has been increasing its dividend for 11 years.Dividend CoverageThe dividend payout ratio of Eli Lilly and Company is 22.46%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 13.83% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.Read more about Eli Lilly and Company's dividend. News and Social Media4.3 / 5News Sentiment0.83 News SentimentEli Lilly and Company has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 132 news articles for Eli Lilly and Company this week, compared to 10 articles on an average week.Search Interest161 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows113 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 131% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,020,770.00 in company stock.Percentage Held by Insiders0.14% of the stock of Eli Lilly and Company is held by insiders.Percentage Held by Institutions82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eli Lilly and Company's insider trading history. Receive LLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LLY Stock News HeadlinesZacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer2 hours ago | finance.yahoo.com4BIO Capital leads $60M Series A financing of Oyster Therapeutics (formerly Kesmalea Therapeutics) to advance next-generation targeted protein degraders for Alzheimer’s and other neurodegenerative diseases2 hours ago | finance.yahoo.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 10 at 1:00 AM | Behind the Markets (Ad)FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundNovember 10 at 2:52 AM | cnbc.comWant to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative (LLY)As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.November 9 at 1:00 PM | marketbeat.comEli Lilly and Company (NYSE:LLY) EVP Sells 5,000 Shares of Company StockNovember 4, 2026 | insidertrades.comGLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge? (LLY)Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to grow.November 2, 2026 | marketbeat.comEli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.November 1, 2026 | marketbeat.comSee More Headlines LLY Stock Analysis - Frequently Asked Questions How have LLY shares performed this year? Eli Lilly and Company's stock was trading at $1,075.00 at the beginning of the year. Since then, LLY stock has increased by 31.5% and is now trading at $1,413.2220. How were Eli Lilly and Company's earnings last quarter? Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings results on Thursday, October, 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm's quarterly revenue was up 38.6% compared to the same quarter last year. Read the conference call transcript. Is Eli Lilly and Company buying back stock? Eli Lilly and Company's board initiated a stock buyback program on Monday, December 9th 2024, which authorizes the company to buy back $15 billion in shares, according to EventVestor. This means that the company could reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued. Does Eli Lilly and Company have any subsidiaries? The following companies are subsidiaries of Eli Lilly and Company: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more. Who are Eli Lilly and Company's major shareholders? Top institutional shareholders of Eli Lilly and Company include Fisher Asset Management LLC (0.58%), Sumitomo Mitsui Trust Group Inc. (0.20%), Fifth Third Bancorp (0.18%) and Sapient Capital LLC (0.16%). Insiders that own company stock include Lilly Endowment Inc, David A Ricks, Daniel Skovronsky, J Erik Fyrwald, Patrik Jonsson, Johna Norton, Jamere Jackson, Anat Hakim, Gabrielle Sulzberger and Donald A Zakrowski. View institutional ownership trends. How do I buy shares of Eli Lilly and Company? Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eli Lilly and Company own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Broadcom (AVGO), Micron Technology (MU), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM). Company Calendar Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Last Earnings10/29/2026Today11/10/2026Record date for 12/10 Dividend11/13/2026Ex-Dividend for 12/10 Dividend11/13/20268th Annual Wolfe Research Healthcare Conference11/13/2026Lilly Innovation Day 202612/07/2026Dividend Payable12/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LLY's financial health is in the Green zone, according to TradeSmith. LLY has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:LLY CIK59478 Webwww.lilly.com Phone(317) 276-2000Fax317-276-4878Employees50,000Year Founded1876Price Target and Rating Average Price Target for Eli Lilly and Company$1,416.64 High Price Target$1,700.00 Low Price Target$900.00 Potential Upside/Downside+0.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$30.81 Trailing P/E Ratio45.87 Forward P/E Ratio28.24 P/E Growth1.77Net Income$20.64 billion Net Margins31.90% Pretax Margin40.21% Return on Equity86.76% Return on Assets22.03% Debt Debt-to-Equity Ratio1.17 Current Ratio1.39 Quick Ratio1.00 Sales & Book Value Annual Sales$65.18 billion Price / Sales20.40 Cash Flow$25.05 per share Price / Cash Flow56.41 Book Value$42.81 per share Price / Book33.01Miscellaneous Outstanding Shares940,740,000Free Float939,428,000Market Cap$1.33 trillion OptionableOptionable Beta0.40 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSE:LLY) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole unt...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredOfficial Black Friday Sale Is Live (Trading Indicator)Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eli Lilly and Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Eli Lilly and Company With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
